Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature

Lenalidomide is indicated in the front-line management of multiple myeloma. More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Forehand III, William, Ajebo, Germame, Toscano, Michael, Jillella, Anand, Dainer, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676979/
https://www.ncbi.nlm.nih.gov/pubmed/33274089
http://dx.doi.org/10.1155/2020/8825618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676979/
https://www.ncbi.nlm.nih.gov/pubmed/33274089
http://dx.doi.org/10.1155/2020/8825618

Ejemplares similares